B of A Securities Maintains Buy on Amicus Therapeutics, Raises Price Target to $15

Benzinga · 10/17 16:59
B of A Securities analyst Tazeen Ahmad maintains Amicus Therapeutics (NASDAQ:FOLD) with a Buy and raises the price target from $13 to $15.